Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Allure Imports
WARNING LETTER
•Allure Imports•March 31, 2021

FDA WARNING_LETTER - Allure Imports - March 31, 2021

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Allure Imports
Record Details

On April 7, 2021, the FDA and FTC issued a Warning Letter to the recipient regarding unapproved and misbranded products related to COVID-19. The FDA and FTC reviewed websites www.facedoctor.ca, www.vitalityc60.com, and www.allureimports.com, and associated social media, on February 25, 2021, and March 31, 2021.

The FDA observed that "Silver Soul Immune Support," "Silver Soul Body Spray," and "Vitality C60" were offered for sale in the U.S. and intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. These products are unapproved new drugs, violating section 505(a) of the FD&C Act, and misbranded drugs under section 502. "Vitality C60" is also intended for COVID-19 mitigation/treatment/prevention in animals, making it an unsafe and adulterated drug under sections 512(a) and 501(a)(5) of the FD&C Act, as it lacks required approvals.

The letter cites specific claims from the websites and social media, such as "Colloidal Silver for Coronavirus" and claims that C60 "boosts dogs' immune systems" and helps "fight off this novel pathogen."

The

Company
Allure Imports
Inspection Date
March 31, 2021
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Donald D. Ashley (Director)
  • Eric M. Nelson (Director - Division of Compliance)
  • Serena Viswanathan (Associate Director)
Open in Dashboard

ID · 711d9dfb-0b0f-4e19-86ea-41914a1c552a

Violation Codes10
21 U.S.C. 331(a)21.U.S.C. 355(a)21 U.S.C. 35221 U.S.C. 321(g)(1)(B)21 U.S.C. 360b21 U.S.C. 360ccc21 U.S.C. 360ccc-121 U.S.C. 360b(a)21 U.S.C. 351(a)(5)21 U.S.C. 331(d)

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.